Dashboard
Manage Tickers

BCRXBIOCRYST PHARMACEUTICALS INC

Nasdaq biocryst.com


$ 7.86 $ 0.36 (4.79 %)    

Tuesday, 06-Aug-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 437.58 $ 4.16 (0.96 %)
DIA $ 389.72 $ 3.15 (0.81 %)
SPY $ 522.63 $ 4.77 (0.92 %)
TLT $ 96.88 $ -2.21 (-2.24 %)
GLD $ 220.73 $ -1.78 (-0.8 %)
$ 7.87
$ 7.85 x 500
$ 7.87 x 469
-- - --
$ 4.03 - $ 7.93
3,848,337
na
1.62B
$ 0.87
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 02-27-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-07-2023 06-30-2023 10-Q
6 05-08-2023 03-31-2023 10-Q
7 02-27-2023 12-31-2022 10-K
8 11-04-2022 09-30-2022 10-Q
9 08-05-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 02-28-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-09-2021 06-30-2021 10-Q
14 05-07-2021 03-31-2021 10-Q
15 03-01-2021 12-31-2020 10-K
16 11-06-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-13-2020 12-31-2019 10-K
20 11-08-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-14-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-09-2018 06-30-2018 10-Q
26 05-09-2018 03-31-2018 10-Q
27 03-12-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-08-2017 03-31-2017 10-Q
31 02-27-2017 12-31-2016 10-K
32 11-08-2016 09-30-2016 10-Q
33 08-08-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 02-26-2016 12-31-2015 10-K
36 11-06-2015 09-30-2015 10-Q
37 08-07-2015 06-30-2015 10-Q
38 05-08-2015 03-31-2015 10-Q
39 03-02-2015 12-31-2014 10-K
40 11-07-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

jmp-securities-maintains-market-outperform-on-biocryst-pharma-raises-price-target-to-16
JMP Securities Maintains Market Outperform...
08/06/2024 17:04:42

JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and raises the pri...

barclays-maintains-equal-weight-on-biocryst-pharma-raises-price-target-to-7
Barclays Maintains Equal-Weight on BioCrys...
08/06/2024 12:53:22

Barclays analyst Gena Wang maintains BioCryst Pharma (NASDAQ:BCRX) with a Equal-Weight and raises the price target from $6 t...

rbc-capital-reiterates-outperform-on-biocryst-pharma-maintains-10-price-target
RBC Capital Reiterates Outperform on BioCr...
08/06/2024 12:34:38

RBC Capital analyst Brian Abrahams reiterates BioCryst Pharma (NASDAQ:BCRX) with a Outperform and maintains $10 price target.

hc-wainwright--co-reiterates-buy-on-biocryst-pharma-maintains-30-price-target
HC Wainwright & Co. Reiterates Buy on BioC...
08/06/2024 10:30:00

HC Wainwright & Co. analyst Andrew Fein reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $30 price target.

biocryst-pharmaceuticals-says-it-expects-to-achieve-full-year-operating-profit-in-2024-approach-quarterly-positive-eps-and-positive-cash-flow-in-2h-of-2025-and-be-profitable-on-an-eps-basis-with-positive-cash-flow-for-full-year-2026
BioCryst Pharmaceuticals Says It Expects T...
08/05/2024 11:07:36

biocryst-pharmaceuticals-has-raised-its-2024-orladeyo-revenue-guidance-to-420m-435m-up-from-390m-400m
BioCryst Pharmaceuticals Has Raised Its 20...
08/05/2024 11:05:51

biocryst-pharma-q2-2024-gaap-eps-006-beats-018-estimate-sales-109332m-beat-98319m-estimate
BioCryst Pharma Q2 2024 GAAP EPS $(0.06) B...
08/05/2024 11:02:38

biocryst-announced-data-showing-reductions-in-attack-rates-in-hae-patients-with-normal-c1-inhibitor-after-beginning-orladeyo-treatment
BioCryst Announced Data Showing Reductions...
06/02/2024 14:46:30

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced new real-world evidence showing that patients with hereditary angi...

why-bolt-biotherapeutics-shares-are-trading-lower-by-around-34-here-are-other-stocks-moving-in-wednesdays-mid-day-session
Why Bolt Biotherapeutics Shares Are Tradin...
05/15/2024 17:38:38

biocryst-pharmaceuticals-form-4-filings-shows-cco-charles-k-gayer-bought-30000-shares-at-an-average-price-of-547share-ceo-jon-p-stonehouse-bought-30000-shares-at-an-average-price-of-555share-steven-k-galson-bought-21940-shares-at-an-average-price-of-549share--helen-m-thackray-bought-30000-shares-at-an-average-price-of-586share-anthony-doyle-bought-36300-shares-at-an-average-price-of-557share
BioCryst Pharmaceuticals Form 4 Filings Sh...
05/15/2024 16:26:53

- SEC Filing

nextracker-posts-upbeat-earnings-joins-mondaycom-nu-holdings-and-other-big-stocks-moving-higher-on-wednesday
NEXTracker Posts Upbeat Earnings, Joins mo...
05/15/2024 14:21:59

biocryst-presents-new-real-world-evidence-showing-significant-reductions-in-healthcare-resource-utilization-among-patients-with-hereditary-angioedema-following-initiation-of-orladeyo-berotralstat
BioCryst Presents New Real-world Evidence ...
05/09/2024 11:41:50

jmp-securities-maintains-market-outperform-on-biocryst-pharma-raises-price-target-to-15
JMP Securities Maintains Market Outperform...
05/07/2024 15:29:42

JMP Securities analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and raises the pri...

hc-wainwright--co-reiterates-buy-on-biocryst-pharma-maintains-30-price-target
HC Wainwright & Co. Reiterates Buy on BioC...
05/07/2024 10:16:41

HC Wainwright & Co. analyst Andrew Fein reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $30 price target.

needham-reiterates-buy-on-biocryst-pharma-maintains-12-price-target
Needham Reiterates Buy on BioCryst Pharma,...
05/07/2024 09:33:05

Needham analyst Serge Belanger reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $12 price target.

biocryst-pharmaceuticals-fantastic-q1-earnings-rides-on-outstanding-orladeyo-performance
BioCryst Pharmaceuticals 'Fantastic' Q1 Ea...
05/06/2024 18:59:35

BioCryst's impressive first-quarter earnings report surpasses estimates. Sales surged to $92.8 million, primarily driven by...

why-perficient-shares-are-trading-higher-by-around-53-here-are-20-stocks-moving-in-mondays-mid-day-session
Why Perficient Shares Are Trading Higher B...
05/06/2024 16:32:34

biocryst-forecasts-2024-orladeyo-revenue-of-390m-400m-the-top-end-of-its-prior-guidance-range-of-380m-400m
Biocryst Forecasts 2024 Orladeyo Revenue O...
05/06/2024 11:05:22

biocryst-pharma-q1-2024-adj-eps-017-beats-021-estimate-sales-92761m-beat-85605m-estimate
BioCryst Pharma Q1 2024 Adj EPS $(0.17) Be...
05/06/2024 11:03:10

biocryst-pharmaceuticals-announced-that-the-brazilian-health-regulatory-agency-has-granted-approval-for-oral-once-daily-orladeyo-berotralstat-for-the-prophylaxis-of-hereditary-angioedema-hae-attacks-in-adults-and-pediatric-patients-12-years
BioCryst Pharmaceuticals Announced That Th...
04/17/2024 08:36:06

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION